Celldex Therapeutics
CLDX
CLDX
182 hedge funds and large institutions have $2.58B invested in Celldex Therapeutics in 2024 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 81 increasing their positions, 49 reducing their positions, and 36 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
less ownership
Funds ownership: →
less funds holding
Funds holding: →
11% less capital invested
Capital invested by funds: $2.91B → $2.58B (-$333M)
33% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 36
80% less call options, than puts
Call options by funds: $3.39M | Put options by funds: $17M
Holders
182
Holding in Top 10
6
Calls
$3.39M
Puts
$17M
Top Buyers
| 1 | +$31.5M | |
| 2 | +$24.2M | |
| 3 | +$20.7M | |
| 4 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$18.1M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$17.7M |
Top Sellers
| 1 | -$70.2M | |
| 2 | -$27.3M | |
| 3 | -$11.9M | |
| 4 |
AG
Artal Group
Luxembourg
|
-$10.6M |
| 5 |
Renaissance Technologies
New York
|
-$9.98M |